- Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…Endpoints · 26d ago↗ source
- FDA says Zyn can market its pouches as safer than cigarettesThe influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning RoundsSTAT · 26d ago↗ source
- STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patientsThe FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.